Charter Trust Co. raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the second quarter, Holdings Channel reports. The institutional investor owned 202,496 shares of the company’s stock after buying an additional 4,203 shares during the period. Johnson & Johnson comprises 2.9% of Charter Trust Co.’s holdings, making the stock its 6th largest position. Charter Trust Co.’s holdings in Johnson & Johnson were worth $24,562,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Capital Investment Advisors LLC boosted its stake in Johnson & Johnson by 13.1% in the first quarter. Capital Investment Advisors LLC now owns 102,964 shares of the company’s stock worth $11,141,000 after buying an additional 11,892 shares in the last quarter. Culbertson A N & Co. Inc. acquired a new stake in Johnson & Johnson during the first quarter worth $7,737,000. Cue Financial Group Inc. boosted its stake in Johnson & Johnson by 5.5% in the first quarter. Cue Financial Group Inc. now owns 11,767 shares of the company’s stock worth $1,273,000 after buying an additional 615 shares in the last quarter. Mission Wealth Management LLC boosted its stake in Johnson & Johnson by 61.9% in the first quarter. Mission Wealth Management LLC now owns 27,785 shares of the company’s stock worth $3,006,000 after buying an additional 10,628 shares in the last quarter. Finally, Iberiabank Corp boosted its stake in Johnson & Johnson by 7.7% in the first quarter. Iberiabank Corp now owns 46,368 shares of the company’s stock worth $5,017,000 after buying an additional 3,297 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.59% on Friday, hitting $117.56. The company had a trading volume of 5,640,519 shares. The stock has a market cap of $321.63 billion, a PE ratio of 21.91 and a beta of 0.62. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07. The company has a 50-day moving average of $118.72 and a 200 day moving average of $117.37.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Analysts anticipate that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
A number of analysts have weighed in on JNJ shares. Barclays PLC restated an “overweight” rating and issued a $125.00 price target (up from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Jefferies Group raised their price objective on Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a report on Thursday, July 14th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a report on Wednesday, July 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $132.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 20th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.